Clinical outcomes of dupilumab therapy in chronic rhinosinusitis with nasal polyps in a Canadian tertiary care rhinology practice

In 2020, dupilumab became the first monoclonal antibody therapy to be approved by Health Canada for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The primary aim of this study was to char...

Source: Allergy, Asthma and Clinical Immunology - March 30, 2023 Category: Allergy & Immunology Authors: Elysia Grose, Alyssa Y. Li and John M. Lee Tags: Research Source Type: research